HLA-A and cancer: In line with these findings, MEL5 TCR was capable of mounting a significantly stronger response to HLA‐A*02:01 positive melanoma cell lines than DMF4, while remaining inert to HLA‐A*02:01 or Melan‐A negative cancer cells (Fig. 1B, right panel; Supporting Information Fig. S1B).